GSK,NVS,SNY -

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal42 minutes ago

    [$$] Philippines Probes Dengue Vaccination Drive That Went Ahead Despite Warnings

    Lawmakers in the Philippines are scrutinizing government decisions to pursue the wide-scale introduction of the world’s first dengue vaccine despite objections from government experts, and continue its ...

  • The Wall Street Journal5 hours ago

    [$$] Manila Investigates Dengue Vaccination Drive

    MANILA—Lawmakers in the Philippines are scrutinizing government decisions to approve and pursue the wide-scale introduction of the world’s first dengue vaccine despite objections from state experts, and ...

  • GuruFocus.com10 hours ago

    Stocks That Fell to 3-Year Lows in the Week of Dec. 15

    General Electric Co. (GE), GlaxoSmithKline PLC (GSK), Ferrellgas Partners LP (FGP) and Crescent Point Energy Corp. (CPG) have declined to their respective three-year lows.

  • Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
    Zacks2 days ago

    Mylan Announces IPR Proceedings for Sanofi's Lantus Patents

    Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.

  • CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More
    Zacks2 days ago

    CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More

    The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.

  • Alnylam Gets Some Welcome News
    Motley Fool2 days ago

    Alnylam Gets Some Welcome News

    A trial that had been on clinical hold because of a patient death has been cleared to restart.

  • Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations
    Zacks2 days ago

    Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

    Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.

  • Capital Cube2 days ago

    ETFs with exposure to Novartis AG : December 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novartis AG Here are 5 ETFs with the largest exposure to NVS-US. Comparing the performance and risk of Novartis AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Beware: Price Wars For Big Pharma, Biotech Companies On Horizon
    Investor's Business Daily2 days ago

    Beware: Price Wars For Big Pharma, Biotech Companies On Horizon

    The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.

  • Investor's Business Daily3 days ago

    The FDA Just Blessed A Hemophilia Trial From This Biotech

    Alnylam edged up Friday after the FDA lifted its clinical hold on trials of a hemophilia drug, allowing Alnylam to start administering the drug before year-end.

  • Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
    Zacks3 days ago

    Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

    This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

  • Sanofi Wants to Go It Alone -- Good Luck With That
    Bloomberg3 days ago

    Sanofi Wants to Go It Alone -- Good Luck With That

    The French drugmaker's in-house R&D efforts have been unimpressive.

  • Lilly Issues Guidance for 2018, New Drugs to Drive Top Line
    Zacks4 days ago

    Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

    Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkey4 days ago

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
    Motley Fool4 days ago

    Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

    An immuno-oncology drug that's in the works could generate significant revenue growth someday.

  • Regeneron, Sanofi Report Positive Top Line Skin Cancer Data
    Zacks4 days ago

    Regeneron, Sanofi Report Positive Top Line Skin Cancer Data

    Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.

  • Benzinga5 days ago

    ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

    The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was ...

  • Top 10 Generic Pharmaceutical Companies In 2017
    Insider Monkey5 days ago

    Top 10 Generic Pharmaceutical Companies In 2017

    The top 10 generic pharmaceutical companies in 2017 operate in the relatively recession-proof pharmaceuticals industry which is immune from the vagaries of economic cycles. The huge R&D expense and expertise required to develop new medicines is a big entry barrier and the patent laws allow pharmaceuticals companies to make monopolistic profits for a new product […]

  • Reuters5 days ago

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's (SASY.PA) promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reuters5 days ago

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reuters5 days ago

    Novartis generics arm says may sell or end some products

    Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday. "In response to high price pressure, we are optimizing our U.S. portfolio. "As we continue to refine our portfolio, it is clear that the U.S. market is a very important market for Sandoz and will continue to be in the future," it added.

  • Glaxo's Nucala Label Expansion Application Gets FDA Approval
    Zacks5 days ago

    Glaxo's Nucala Label Expansion Application Gets FDA Approval

    GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

  • Reuters5 days ago

    Sanofi CEO says M&A targets in oncology are 'very expensive'

    PARIS (Reuters) - Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very expensive". "If you are not starting with ...

  • Reuters5 days ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • Reuters5 days ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON, Dec 12 (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.